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Article
Traditional and emerging indicators
of cardiovascular risk in chronic
obstructive pulmonary disease
Michelle John1, Tricia M McKeever2, Maath Al Haddad1,
Ian P Hall1, Ian Sayers1, John R Cockcroft3
and Charlotte E Bolton1
Abstract
With the increased cardiovascular (CV) morbidity and mortality in subjects with chronic obstructive
pulmonary disease (COPD), there is a priority to identify those patients at increased risk of cardiovascular
disease. Stable patients with COPD (n¼ 185) and controls with a smoking history (n¼ 106) underwent aortic
pulse wave velocity (PWV), blood pressure (BP) and skin autofluorescence (AF) at clinical stability. Blood was
sent for fasting lipids, soluble receptor for advanced glycation end products (sRAGE) and CV risk prediction
scores were calculated. More patients (18%) had a self-reported history of CV disease than controls (8%),
p ¼ 0.02, whilst diabetes was similar (14% and 10%), p ¼ 0.44. Mean (SD) skin AF was greater in patients: 3.1
(0.5) AU than controls 2.8 (0.6) AU, p < 0.001. Aortic PWV was greater in patients: 10.2 (2.3) m/s than
controls: 9.6 (2.0) m/s, p¼ 0.02 despite similar BP. The CV risk prediction scores did not differentiate between
patients and controls nor were the individual components of the scores different. The sRAGE levels were not
statistically different. We present different indicators of CV risk alongside each other in well-defined subjects
with and without COPD. Two non-invasive biomarkers associated with future CV burden: skin AF and aortic
PWV are both significantly greater in patients with COPD compared to the controls. The traditional CV
prediction scores used in the general population were not statistically different. We provide new data to
suggest that alternative approaches for optimal CV risk detection should be employed in COPD management.
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Introduction
The increased cardiovascular (CV) risk in patients
with chronic obstructive pulmonary disease (COPD)
has been the subject of great research interest, partic-
ularly as itis an important cause of the excess morbid-
ity and mortality in patients compared to people
without COPD.1,2 However, routinely assessing CV
state, predicting CV risk or considering primary pre-
ventative strategies in patients with COPD are not part
of guidelines and are not routinely performed in clin-
ical practice, no doubt in part as the optimal method
remains uncertain.
In the general population, CV risk prediction
scores can assess the likelihood of future CV events
or mortality.3,4 There are caveats in that they are not
universally performed5 and are not applicable for
people with pre-existent CV disease and some are not
suitable for those with diabetes mellitus; these other
conditions in themselves influence future CV risk
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greater. Further, in certain disease states such as rheu-
matoid arthritis, modification of the CV risk predic-
tion algorithm has been required to enhance their
prognostication.6 Despite these considerations, they
are a standard method for detecting risk in the com-
munity population. Of importance though, there is
growing awareness that multimorbidity might require
a fresh approach to assessment and management,
where traditional risk factors are combined with other
less identified factors that enhance risks.7,8 The utility
of the traditional CV risk prediction scores in patients
with COPD has not been assessed.
Alternative methods for determining CV risk have
been proposed. Several studies have consistently
reported increased aortic stiffness in patients with
COPD compared to age- and gender-matched controls
with a smoking history.9,10 Aortic stiffness, using aor-
tic pulse wave velocity (PWV) is an independent pre-
dictor of CV disease in this age group of subjects but
is not, as yet, a clinical measure in everyday practi-
ce.11,12.Aortic stiffness adds to the traditional CV risk
factors in predicting risk in the Framingham cohort.13
The contribution of advanced glycation end prod-
ucts (AGE; markers of glycaemic and oxidative
stress, pro-inflammatory and altering structure
through collagen cross-linking), its receptor (RAGE)
and the soluble decoy receptor: sRAGE in COPD
pathology have been studied recently.14–18 Skin auto-
fluorescence (AF) permits a non-invasive measure-
ment of skin AGE and has been validated against
the skin biopsy gold standard.19 Skin AF reflects tis-
sue accumulation of oxidative stress, unlike circulat-
ing AGE levels that are more variable, affected by
diet20 and crucially in a lung disease such as COPD,
by smoking.21 In patients with COPD, skin AF is
increased compared to controls22 and there are age-
related increases.
Skin AF has been associated with CV and renal risk
factors23 and reported as a useful clinical adjunct
when evaluating both fatal and non-fatal CV events,
and total mortality in different populations.24–26 Asso-
ciations between skin AF and cardiovascular risk
measures such as arterial stiffness in patients with
end-stage renal disease have been reported.27 Low
sRAGE is associated with future CV disease,28 whilst
the tissue receptor for AGE has been implicated in
structural vascular wall changes and a role in
atherosclerosis.29
We set out to assess CV risk parameters in well-
characterized patients with COPD and controls with a
smoking history using multiple approaches, including
currently recognised CV risk scores used in the gen-
eral population and other emerging indicators includ-
ing aortic stiffness and skin AF. Here, we report the
different approaches alongside each other for the first
time in COPD.
Methods
Subjects
Consenting patients with confirmed COPD30
(n ¼ 185) and gender-matched controls free from
respiratory disease and symptoms (n ¼ 106) were
recruited during 2011–2013 from volunteer data-
bases, outpatient clinics and by advertisement. All
subjects were over 40 years of age, of European
descent, had a smoking history of greater than
10 pack-years and were studied at clinical stability.
All subjects gave written informed consent and the
study was approved by the National Research Ethics
Committee (10/H0406/65). No one had active or
suspected malignancy, terminal disease or known
a1 antitrypsin deficiency.
Cardiovascular measurements
Patients were asked to refrain from short-acting
bronchodilators for a minimum of 4 hours and long-
acting bronchodilators for >12 hours prior to the
study. All subjects were asked to refrain from caffeine
products for >6 hours. Tests were performed after a
period of resting supine for >10 minutes. Heart rate
(HR) and peripheral blood pressure (BP) were per-
formed in the seated position and the mean of two
technically acceptable results was recorded (Omron
705IT, UK). Pulse pressure (PP) and mean arterial
pressure (MAP) were calculated. Aortic PWV was
performed using Vicorder (Skidmore Medical, UK)
using a thigh cuff to measure femoral pulse and a
partial cuff around the neck at the level of the carotid
artery. Sequentially recorded carotid and femoral
artery waveforms allowed calculation of wave transit
time. Aortic PWV was determined by dividing path
length by wave transit time, which was measured in
triplicate and the average recorded.31
Anthropometry and lung function
Height and weight were measured (Seca, Germany)
and body mass index (BMI) calculated. Fat-free mass
(FFM) was calculated using bioelectrical impedance
analysis (Tanita 418, Japan). A height-squared FFM
index (FFMI) was calculated.
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Post-bronchodilator spirometry was performed
(Microlab MK6, Micromedical, UK) to determine
forced expiratory volume in 1 second (FEV1) and
forced vital capacity (FVC). Oxygen saturations after
10 minutes rest (Konica Minolta Pulsox-300) breath-
ing air and exhaled carbon monoxide levels were per-
formed (Clement Clarke International, UK).
Biochemistry
Venous blood was taken for fasting lipids. Lipid pro-
file analytes were measured on the Olympus AU2700
platform (Beckman Coulter, Brea, California, USA).
Estimated glomerular filtration rate (eGFR) was cal-
culated.32 Serum was centrifuged, aliquoted and
stored at 80C for later determination of circulating
sRAGE (R&D systems, UK) by enzyme-linked
immunosorbent assay in duplicate.
Other measurements
Detailed medical, medication and smoking history
were recorded. Past medical history was collected
by detailed questioning to the patient and patient con-
sent for access to Trust medical records. The COPD
assessment tool (CAT) and St George’s Respiratory
Questionnaire (SGRQ) were completed.33,34
Cardiovascular risk scores
Cardiovascular risk scores were calculated to deter-
mine the risk of a CV event in the next 10 years using
the National Heart, lung, Blood Institute (NHLBI)3
and American College of Cardiology/American Heart
Association (ACC/AHA)4 equations. The NHLBI is
not suitable for subjects with ischaemic heart disease
(IHD) or diabetes and therefore was performed on a
subgroup. The ACC/AHA calculator permits inclusion
of diabetics but is not suitable for those with IHD,
therefore again performed on a (different) subgroup.
Statistics
Data were analysed using Statistical Package for the
Social Sciences (SPSS, Chicago, Illinois, USA) ver-
sion 21.0. The main analyses compared skin AF and
aortic stiffness between the patients with COPD and
controls using independent t-tests.
At recruitment, we purposely did not exclude sub-
jects with co-existent IHD or diabetes mellitus. This
was in order to represent clinical practice as much as
possible. However, we opted a priori to compare the
key variables between patients with COPD and
controls in the subgroup without evidence of IHD or
diabetes. Further, as above, the CV risk score calcula-
tions were only possible in subgroups.
Normally distributed data were presented as mean
and SD and where possible, non-normally data (e.g.
sRAGE) was log10 transformed in order to perform
parametric analysis and presented as geometric mean
and SD. Non-parametric tests were performed on age,
smoking pack-years and carbon monoxide, with
results presented as median and interquartile range.
Chi-squared test was used to compare categorical data
between groups, including gender and smoking status.
A p < 0.05 was considered significant.
Multiple stepwise linear regression was performed
to adjust analyses for accepted confounders such as age
and gender where appropriate. The association
between skin AF and other key variables were assessed
in a multiple forward linear regression in patients.
Independent variables of interest were entered if sig-
nificant at the p < 0.1 level in univariate analysis. The
skin AF was the dependent variable and the indepen-
dent variables of age, gender, FEV1% predicted, pres-
ence of IHD and diabetes entered into the model.
A power calculation indicated that to determine a
10% difference in skin AF between patients with
COPD and controls, with 90% power and a SD of
0.5 arbitrary units (AU), 292 subjects were required.
This would also give >90% power to detect a 10%
difference in aortic PWV between groups with a SD
of 2.2 m/s and provide over 99% power at the 5%
significance level to detect a 0.2 AU difference in
AF per 10% increase FEV1% predicted, assuming
linear effects.
Results
Demographic data including gender proportion and
BMI were similar between patients with COPD and
controls, as shown in Table 1. The patients were mar-
ginally older. Resting oxygen saturations breathing
air were <92% in 13 patients with COPD but not in
controls. There were significantly more patients
(18%) with self-reported IHD compared to controls
(8%), p¼ 0.02; and 14% of patients and 10% controls
with diabetes, p ¼ 0.44, as shown in Table 2.
CV risk scores are not significantly greater
in patients with COPD compared to controls
The CV risk scores were performed where eligible:
the NHLBI risk score was performed in 132 patients
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and 88 controls and the ACC/AHA risk score in
152 patients and 98 controls. Neither score demon-
strated a significant difference in 10-year CV risk
between patients and controls, as presented in Table 3.
The proportions with a 10-year CV risk score >10%35
were similar between patients (NHLBI: 54%, ACC/
AHA: 75%) and controls (NHLBI: 44%, ACC/AHA:
64%), NHLBI p ¼ 0.17 and ACC/AHA p ¼ 0.069.
There were no significant differences between
patients and controls for any of the individual compo-
nents of the CV risk scores including BP, total or
HDL–cholesterol, current smoking status or propor-
tion on antihypertensive or other CV medication.
Skin AF is elevated in patients with COPD
The mean (SD) skin AF was greater in patients with
COPD, 3.1 (0.5) AU, compared with controls,
2.8(0.6), p < 0.001 and remained significant
after adjusting for age and gender (p ¼ 0.001),
although marginally weaker (b [95% CI] went from
Table 1. Demographics of study population.a
COPD
(n ¼ 185)
Control
(n ¼ 106) p Value
Age (years)b 68 (57–79) 66 (54–78) 0.04
Gender (male n %) 116 (63) 65 (61) 0.87
Smoking status %
current
30% 21% 0.09
Smoking pack-years
(pack-years)b
42 (15–69) 23 (13–49) <0.001
FEV1 (l) 1.6 (0.6) 2.8 (0.7) <0.001
FEV1% predicted (%) 58 (18) 100 (14) <0.001
FEV1/FVC ratio 49 (13) 74 (7) <0.001
Resting oxygen
saturations (%)b
95 (94–96) 96 (95–97) <0.001
Carbon monoxide
(ppm)b
3 (1–13) 2(1–6) 0.0661
CAT score 19 (9) 7 (6) <0.001
SGRQ total score 40 (21) 8 (9) <0.001
BMI (kg/m2) 27.2 (5.5) 27.8 (4.6) 0.32
FFMI (kg/m2;
175 patients,
102 controls)
18.4 (2.8) 18.9 (2.3) 0.12
BMI: body mass index; CAT: COPD assessment test; FEV1: forced
expired volume in 1 second; FEV1/FVC: forced expired volume in
1 second to forced vital capacity ratio; FFMI: fat-free mass index;
SGRQ: St George’s Respiratory Questionnaire.
aPresented as mean and SD unless otherwise stated.
bmedian (inter-quartile range),
Table 2. Self-reported comorbidities and medications.a
COPD
(n ¼ 185)
Control
(n ¼ 106)
p
Value
IHD n (%) 33 (18) 8 (8) 0.02
Diabetes n (%) 25 (14) 11 (10) 0.44
Statins n (%) 71 (38) 32 (30) 0.21
Other antihypertensive/CV
medication n (%)
81 (44) 34 (32) 0.09
ICS n (%) 117 (63) 0
CV: cardiovascular; IHD: ischaemic heart disease; ICS: inhaled
corticosteroids.
aOther CV medication included beta blockers, ACE inhibitors,
angiotensin receptor blockers and calcium channel blockers
Table 3. Haemodynamic status and cardiovascular risk
scores.
Mean (SD) unless
otherwise indicated
COPD
(n ¼ 185)
Control
(n ¼ 106)
p
Value
Skin AGE (AU) 3.1 (0.5) 2.8 (0.6) <0.001
Aortic PWV (m/s) 10.2 (2.3) 9.6 (2.0) 0.02
Peripheral systolic
BP (mmHg)
146 (22) 146 (17) 0.95
Peripheral diastolic
BP (mmHg)
84 (11) 85 (11) 0.74
Peripheral PP
(mmHg)
62 (17) 61 (14) 0.90
Peripheral MAP
(mmHg)
105 (13) 105 (12) 0.82
HR (bpm) 75 (15) 71 (12) 0.01
Central PP (mmHg) 58 (17) 58 (13) 1.0
Central MAP (mmHg) 110 (14) 111 (12) 0.67
Total cholesterol
(mmol/L)
5.1 (1.2) 5.3 (1.2) 0.13
LDL cholesterol
(mmol/L)
2.7 (1.0) 2.9 (1.0) 0.16
HDL cholesterol
(mmol/L)
1.7 (0.5) 1.6 (0.4) 0.32
sRAGE (pg/mL)a 949.9 (1.7) 1057.1 (1.6) 0.09
eGFR (mL/min) 70 (14) 73 (12) 0.24
ACC/AHA CV risk
score (COPD
n ¼ 152, controls
n ¼ 98)
20.2 (13.5) 17.4 (12.7) 0.09
NHLBI CV risk score
(COPD n ¼ 132,
controls n ¼ 88)
10.9 (7.8) 10.3 (7.9) 0.54
PP: pulse pressure; ACC/AHA: American College of Cardiology/
American Heart Association; BP: blood pressure; eGFR: esti-
mated glomerular filtration rate; MAP: mean arterial pressure;
NHLBI: National Heart, Lung and Blood Institute; PWV: pulse
wave velocity; sRAGE: soluble receptor for AGE; AGE: advanced
glycation end products; COPD: chronic obstructive pulmonary
disease; HR: heart rate.
aGeometric mean.
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0.252 [0.385, 0.12] to 0.216 [0.343,
0.086]).In the subgroup without IHD or diabetes,
the skin AF remained greater in patients with COPD
3.0(0.5) AU than controls 2.7(0.5) AU, p ¼ 0.001 and
again remained significant after adjustment for con-
founders of age and gender, p ¼ 0.003.
Skin AF in relation to self-reported
IHD and diabetes
There was no significant difference in the skin AF of
patients with COPD with and without IHD, p ¼ 0.18.
There was a significant difference in skin AF between
patients with COPD who had diabetes n ¼ 25,
3.4 (0.6) AU and those without n ¼ 160, 3.0 (0.5)
AU; p ¼ 0.002.
Variables associated with skin AF
Skin AF was related to chronological age in patients,
r ¼ 0.146, p ¼ 0.047 and controls r ¼ 0.368,
p < 0.001. It was inversely related to FEV1% pre-
dicted in the COPD group, r ¼ 0.20, p ¼ 0.005 but
not in controls, r ¼ 0.050, p ¼ 0.608.There was no
correlation between skin AF and either eGFR or
smoking pack-years in the patients or controls. Skin
AF was not significantly different between current
and ex-smoker patients.
FEV1% predicted, chronological age and
co-existent presence of diabetes were the significant
predators of skin AF and these variables accounted
for 11.6% of the variance of Skin AF, as shown in
Table 4.
Aortic stiffness is increased in patients with COPD
and associated with Skin AF
Aortic PWV was greater in patients with COPD,
10.2 (2.3) m/s compared to the controls, 9.6 (2.0) m/s,
p ¼ 0.02 despite similar MAP (Table 3). In the
subset without self-reported IHD and diabetes, aortic
PWV remained significantly higher in patients with
COPD (n ¼ 132) 10.1 (2.2) m/s compared to con-
trols (n ¼ 88) 9.3 (1.9) m/s, p ¼ 0.006.
In patients, aortic PWV was not related to FEV1%
predicted but was to age (r ¼ 0.351, p < 0.001) and
MAP (r ¼ 0.218, p ¼ 0.004).The association with
MAP was not altered when adjusted for age and
gender.
In the patients, the association between the aortic
PWV and skin AF was r ¼ 0.18, p ¼ 0.01 and was
weakened after adjustment for age and gender,
p ¼ 0.06 (b [95% CI] went from 0.744 [0.147, 1.34]
to 0.478 [0.095, 1.05].
There were 95 (51%) patients and 41 (39%) con-
trols with an aortic PWV >10 m/s, p¼ 0.039. The skin
AF was greater in patients with a high aortic PWV:
3.10 (0.55) AU compared to those with a PWV
<10 m/s: 2.85 (0.55) AU, p < 0.001. This remained
significant after adjustment for age and gender,
p ¼ 0.047.
sRAGE is not different between patients
with COPD and controls
The geometric mean (SD) sRAGE was not signifi-
cantly different between patients with COPD
(n ¼ 182): 957.8(1.7) pg/mL and controls
(n ¼ 105): 1057.0 (1.6) pg/mL p ¼ 0.13. However,
in the subgroup without IHD or diabetes, sRAGE was
significantly lower in patients: 891.3 (1.7) pg/mL
compared to controls: 1079.2 (1.7) pg/mL p ¼ 0.01.
Log10 sRAGE was not related to skin AF;
r ¼ 0.08, p ¼ 0.25. In patients there was a signifi-
cant difference in sRAGE between those with self-
reported IHD n ¼ 33:1245.9 (1.72) pg/mL and those
without n ¼ 149:894.5 (1.69) pg/mL p < 0.01. How-
ever, there was no difference in sRAGE between
patients with and without diabetes. There was no
association of sRAGE to aortic PWV.
Discussion
Patients with COPD have both a significantly greater
skin AF and aortic stiffness than controls with a smok-
ing history. Although there was a greater prevalence
of self-reported IHD in patients with COPD compared
to the control group, the 10-year future CV risk score
calculators did not significantly distinguish between
the two subject groups. Taken together, this work
Table 4. Factors associated with skin AF in patients with
COPD.
Dependent variable: Skin AF
B 95% CI
Diabetes (yes) 0.34 0.27 to 0.60
FEV1% predicted (per %) 0.005 0.007 to 0.003
Age (per year) 0.015 0.008 to 0.022
CI: confidence interval; AF: autofluorescence; FEV1: forced
expiratory volume in 1 second; COPD: chronic obstructive pul-
monary disease.
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suggests that alternative strategies might need to be
employed to best detect future CV risk in COPD.
Skin AF has been shown to be a measure of long-
term metabolic burden which has been strongly asso-
ciated with CV disease and mortality in patients with
diabetes,24 CV risk factors in renal disease,23 those
with a CV history36 and also subclinical and clinical
atherosclerosis independent of diabetes and renal dis-
ease.25 It is a straightforward, quick, non-invasive
measurement and this work extends previously pub-
lished work22 demonstrating increased skin AF in
patients with COPD across a range of moderate to
very severe airways obstruction by considering the
CV implications of increased skin AF.
Although there was no difference in skin AF
between those with and without self-reported IHD,
an important consideration is the likely subclinical
CV disease in COPD,37,38 which in itself reinforces
the need to consider a new approach to CV prognos-
tication such as skin AF. We did not objectively
assess presence of IHD with invasive testing or ima-
ging. Nor did we subcategorize self-reported IHD into
a historical acute myocardial infarction or current
symptomatic cardiac ischaemia. Contrary to our find-
ings, Mulder et al. showed that skin AF was higher in
subjects with stable coronary artery disease compared
to controls, however, these subjects had undergone
considerable investigations to establish or exclude
vascular disease.36 Further, skin AF was increased
in those with subclinical atherosclerosis as well as
clinical atherosclerosis, independent of diabetes and
renal disease25 in a study of patients referred to a
vascular clinic.
Once again, aortic PWV, a non-invasive indepen-
dent predictor of CV risk11,31 in this age group of
subjects, was greater in patients with COPD com-
pared to controls, independent of age and gender and
in the setting of similar MAP. The difference was seen
in an unselected group of patients and controls, and
similarly in the subset of patients and controls without
self-reported IHD or diabetes mellitus. The clinical
implications of increased aortic stiffness is growing
for both macrovascular and microvascular dis-
ease39,40 with a 1 m/second increase in aortic PWV
relating to a 15% increase in CV mortality and all-
cause mortality.40 Amongst Framingham participants,
the addition of aortic PWV predicted first CV events
and further, improved the 10-year risk classification
when added to the standard risk factors by 13%.41
Whilst aortic PWV is not in current clinical practice,
there have been discussions on its role as a Food and
Drug Administration outcome42 and developments in
equipment permit cost-effective, user-friendly
options for clinical assessment.
The weak association we reported of skin AF with
aortic stiffness does not detract from skin AF as a
potential prognostic marker for future CV disease24,43
particularly given aortic stiffness is a surrogate in
itself for a hard end point of CV event or death. A
longitudinal study is required. Others have reported
an independent association between skin AF and aor-
tic PWV in patients with type 1 diabetes and with
brachial-ankle PWV in 120 Japanese patients with
end-stage renal failure,27,44 but this is not universally
seen.45
Of note, was the lack of difference in the traditional
CV risk scores between patient and controls. Current
calculators consider smoking categorically as ‘current
smoker or not’ but have no lung disease–related factor
or gradation of smoking exposure. Thus a heavy ex-
smoker with COPD who stopped a few months back
would score less than a control smoker with a
10 pack-year history, provided other variables were
the same. Theoretically, the reported increased CV
risk in patients with COPD could have been attributed
to subtle differences in the other variables, but this
does not seem to be the case. For the small difference
between the groups in proportion with a CV risk
>10%, we lacked power but had the proportions
reflected the fold change in future morbidity and mor-
tality previously reported, the study would have been
powered. Other disease states such as rheumatoid
arthritis have required modification of the risk scores
or introduction of novel methods to account for the
increased risk in that condition. This raises the ques-
tion of whether a modified COPD CV calculator is
required but also opens consideration of other biomar-
kers to detect increased CV risk, which could translate
into meaningful outcome.
A little unexpectedly given previous literature was
that sRAGE levels were not statistically different
between patients and controls overall, however, were
significantly lower in patients in the subgroup without
self-reported IHD and diabetes. Smith et al. previ-
ously reported lower sRAGE levels in patients with
COPD compared to controls, including patients
GOLD II or worse (unlike our study where GOLD I
were also included) and their reported levels were
generally much lower.15 Gopal et al. have similarly
shown lower sRAGE in patients with COPD and
related to lung function.18,46 In that study, sRAGE
was lower in those patients with COPD receiving
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long-term oxygen compared to patients who were
not.46 There are also associations of sRAGE to
emphysema, something we did not assess.16,47 Liter-
ature on sRAGE in patients with and without CV
disease is mixed, though not been studied in patients
with COPD in this respect.48,49 Lastly, genetics may
well also be a potential confounder – we did not take
into account the presence/absence of the single
nucleotide polymorphism in RAGE in our subjects
including, for example, rs2070600 (Gly82Ser, C/T)
that has been identified as a genetic determinant
of serum sRAGE levels,16,50 shown association with
FEV1
17,51 and COPD.52
Limitations
This study group reflects a typical clinical outpatient
population in order to be representative. We opted for
this approach as hidden comorbid disease exists and
excluding a subset with a prior diagnosis is arbitrary.
The study is limited by its cross-sectional design and
reinforces the need for a longitudinal study with hard
endpoints.
Future direction
Prospective, larger, longitudinal studies are needed to
fully evaluate the prognostic value that CV indicators
may offer in identifying a high-risk group of patients
with COPD for future CV disease. This approach
parallels a need for a major shift in the care of patients
with COPD to address the CV risk in patients with
COPD at diagnosis and at assessments. Although fur-
ther work is required to optimize the ideal CV risk
assessment, management of known modifiable risk
factors in a systematic approach such as smoking
cessation, lipid reduction and optimisation of BP
should be considered. Certainly with 30% being cur-
rent smokers in the patient population, there is oppor-
tunity for evidence-based interventions.
Conclusion
Skin AF and aortic stiffness, known independent pre-
dictors of future CV events and death in different
populations are increased in patients with COPD
compared to controls, where, importantly, traditional
CV risk scores alone may not sufficiently identify the
increased risk. A new approach to address and iden-
tify CV risk in patients with COPD is required and a
longitudinal study timely.
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